Target intelligence / Profile preview

Poly [ADP-ribose] polymerase 1 mRNA (PARP1 mRNA)

Target
PARP1 mRNA
Molecular classification
Nucleic acid, Messenger RNA
01

Overview

Poly [ADP-ribose] polymerase 1 (PARP1) mRNA is the messenger RNA transcript that encodes the PARP1 enzyme, a critical factor in the cellular response to DNA damage [NCBI Gene ID: 142]. The PARP1 protein is primarily involved in identifying single-strand DNA breaks and initiating the base excision repair pathway, but it also plays roles in chromatin remodeling and cell death pathways like parthanatos [PubMed: 29128124]. In oncology, PARP1 mRNA is a target for gene-silencing therapies, such as small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs), which aim to deplete the protein to induce synthetic lethality in cancer cells with existing DNA repair defects, such as BRCA1/2 mutations [PubMed: 28677110]. This mRNA-targeting approach is distinct from traditional small-molecule PARP inhibitors, which bind to the protein's catalytic site; silencing the mRNA can potentially bypass resistance mechanisms or avoid the toxicities associated with "PARP trapping" on DNA [PubMed: 31533938]. Beyond cancer, the regulation of PARP1 mRNA is investigated in inflammatory and neurodegenerative diseases where excessive PARP1 activity leads to energy depletion and cell death [PubMed: 25635911]. Consequently, PARP1 mRNA represents a strategic target for precision medicine and nucleic acid-based therapeutics.

Other names
PARP-1 mRNAADPRT mRNAPPOL mRNAARTD1 mRNAPoly(ADP-ribose) synthetase 1 mRNA
02

Mechanism of action

RNA interference (RNAi) or antisense-mediated degradation of the mRNA transcript to prevent translation of the PARP1 protein.

03

Biological functions

Protein synthesis templateRegulation of DNA repairCell death signalingChromatin remodeling regulation
04

Disease associations

CancerBreast cancerOvarian cancerProstate cancerInflammationNeurodegenerative disease
05

Safety considerations

Off-target hybridizationInnate immune response to nucleic acidsDelivery to target tissuesPotential for systemic toxicity from total PARP1 depletion
06

Interacting drugs

siRNA (experimental)

1 more in the full profile.

07

Biomarkers

PARP1 mRNA expression levelsBRCA1/2 mutation statusHomologous recombination deficiency (HRD) score

Beyond the preview

Go deeper on Poly [ADP-ribose] polymerase 1 mRNA (PARP1 mRNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Poly [ADP-ribose] polymerase 1 mRNA (PARP1 mRNA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call